Clinical Trial Update: Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis [Phase 2]

View source ↗

Summary

Phase 2b study of NGM282 for primary biliary cholangitis has completed; the update notes the trial status as COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• NGM282 (Aldafermin) (Aldafermin)

Snippet

Sponsor: NGM Biopharmaceuticals, Inc | Conditions: Primary Biliary Cirrhosis | Phase 2 | Status: COMPLETED